COVID vaccines: calling the shots

25 November 2020 — Michael Roberts

Before the COVID-19 pandemic engulfed the world, the big pharmaceutical companies did little investment in vaccines for global diseases and viruses.  It was just not profitable. Of the 18 largest US pharmaceutical companies, 15 had totally abandoned the field.  Heart medicines, addictive tranquilizers and treatments for male impotence were profit leaders, not defences against hospital infections, emergent diseases and traditional tropical killers.  A universal vaccine for influenza—that is to say, a vaccine that targets the immutable parts of the virus’s surface proteins—has been a possibility for decades, but never deemed profitable enough to be a priority.  So, every year, we get vaccines that are only 50% efficient.

Continue reading

RT-PCR Test to Detect SARS-CoV-2 Reveals 10 Major Scientific Flaws at the Molecular and Methodological Level:

1 December 2020 — Global Research

Consequences for False Positive Results

External Peer Review

By Pieter Borger, Bobby Rajesh Malhotra, and et al.

Corman-Drosten Review Report 27 November 2020

Abstract

In the publication entitled “Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR” (Eurosurveillance 25(8) 2020) the authors present a diagnostic workflow and RT-qPCR protocol for detection and diagnostics of 2019-nCoV (now known as SARS-CoV-2), which they claim to be validated, as well as being a robust diagnostic methodology for use in public-health laboratory settings.

Continue reading

EPA Finds Glyphosate Is Likely to Injure or Kill 93% of Endangered Species

25 November 2020 — Center for Biological Diversity

For Immediate Release, November 25, 2020

Lori Ann Burd, (971) 717-6405, laburd@biologicaldiversity.org

WASHINGTON— The Environmental Protection Agency released a draft biological evaluation today finding that glyphosate is likely to injure or kill 93% of the plants and animals protected under the Endangered Species Act.

Continue reading

What the Leading COVID Vaccine Contenders Still Need to Tell the Public

25 November 2020 — Children’s Health Defense

Given how much we don’t yet know, it’s unclear why those of us asking for more information about the leading COVID vaccines are being marginalised. We’re simply exercising our right to informed consent.

By Rob Verkerk Ph.D

The race is on

When everyone’s trying to pick potential winners of the global race to produce COVID vaccines, spare a thought for those of us who are the guinea pigs. We, the public, as well as concerned doctors and other health professionals, need to be crystal clear about what information we need to give consent — assuming vaccine rollout is not made mandatory in your country or state.

Continue reading

COVID vaccines: calling the shots

25 November 2020 — Michael Roberts

By Michael Roberts

Before the COVID-19 pandemic engulfed the world, the big pharmaceutical companies did little investment in vaccines for global diseases and viruses.  It was just not profitable. Of the 18 largest US pharmaceutical companies, 15 had totally abandoned the field.  Heart medicines, addictive tranquilizers and treatments for male impotence were profit leaders, not defences against hospital infections, emergent diseases and traditional tropical killers.  A universal vaccine for influenza—that is to say, a vaccine that targets the immutable parts of the virus’s surface proteins—has been a possibility for decades, but never deemed profitable enough to be a priority.  So, every year, we get vaccines that are only 50% efficient.

Continue reading

Covid-19 Vaccine?: Maybe, Maybe Not

22 November 2020 — Paleo Diabetic

professor, equationsThe governments “top men” are working on it

Peter Doshi, an associate editor at British Medical Journal, is not favorably impressed with the recent vaccine trial announcements. “90% effective.” “95% effective!”

Coronavirus guru Anthony Fauci assures us that a coronavirus vaccine will only be FDA-approved if it’s “safe and effective.” Continue reading

Revealed: Boris Johnson’s controversial policy chief leading secretive NHS task force

19 November 2020 — Open Democracy

Munira Mirza heading up group meeting ‘daily or weekly’ to plan ‘radical NHS shakeup’

caroline m.jpg

Caroline Molloy

Boris Johnson’s government has for the first time confirmed the existence of a prime ministerial task force which is reportedly planning a “radical shake-up of the NHS”.

Freedom of Information disclosures to openDemocracy show the new “No.10 Health and Social Care Taskforce” reports to a Steering Group chaired by Munira Mirza, the influential head of Boris Johnson’s policy unit, and that it “met weekly” from July to September with a further meeting in October.

Continue reading

Crony Capitalism: This case will reshape society

22 November 2020 — Good Law Project

Kate Bingham heads up Britain’s vaccine task force. She’s a venture capitalist with no public health experience, married to a Conservative minister. Dido Harding leads the Test and Trace system. She has no public health experience and is the wife of a Conservative MP. Mike Coupe, is head of COVID-19 testing, and has – you guessed it – no public health experience. The list goes on.

Continue reading

Covid-19: New evidence on face masks

19 November 2020 — Sebastion Rushworth MD

by Sebastian Rushworth, M.D.

A few months back I wrote an article about the state of the evidence on face masks. At that point, there were no good studies looking at the effectiveness of face masks in preventing the spread of covid-19 specifically, but there was a systematic review that looked at all randomized trials that had been done on face masks for the prevention of respiratory infections more generally. That review found that surgical face masks reduced the probability of getting a respiratory infection by around 4% in absolute terms (17% in relative terms).

Continue reading